NASDAQ$PLSE
Pulse Biosciences Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Pulse Biosciences reported business updates and financial results for the first quarter ended March 31, 2025.
Pulse Biosciences reported a net loss of $16.795 million for Q1 2025, an increase from $10.137 million in Q1 2024. Total costs and expenses increased significantly, driven by non-cash stock-based compensation and administrative expenses. The company is advancing its nsPFA technology with several clinical trials and commercialization efforts.
- Total GAAP costs and expenses for Q1 2025 were $18.0 million, up from $10.6 million in the prior year period.
- GAAP net loss for Q1 2025 was $16.795 million, compared to $10.137 million in Q1 2024.
- Cash and cash equivalents totaled $119.3 million as of March 31, 2025, including $14.1 million from warrant exercises.
- The company is expanding commercial resources for the nsPFA Percutaneous Electrode launch in H2 2025 and commencing new U.S. clinical trials for its nsPFA systems.
Headline financials
Revenue & EPS history
Pulse Biosciences · Revenue · Quarterly
$0
Forward guidance
Pulse Biosciences anticipates expanding commercial efforts and launching the nsPFA Percutaneous Electrode System in the second half of 2025, alongside commencing U.S. IDE pivotal clinical studies for its nsPFA Cardiac Surgery System and nsPFA 360 Cardiac Catheter System in mid-2025.
Tailwinds
- Expanded direct commercial resources for the launch of the nsPFA Percutaneous Electrode expected in the second half of 2025.
- Expects to commence a U.S. clinical trial in mid-2025 for the nsPFA Percutaneous Electrode System as a treatment for benign thyroid nodules.
- Received EU approval to expand the clinical protocol for the nsPFA Cardiac Surgery System multi-center, first-in-human atrial fibrillation (AF) feasibility study.
- Continuing to advance an IDE and remaining on track to receive approval to commence a pivotal clinical trial in mid-2025 for FDA approval of AF treatment.
- Expects to commence a U.S. IDE pivotal clinical study for the nsPFA 360° catheter sometime in the middle of 2025.
Headwinds
- No specific negative forward guidance was provided in the report.
- The company's financial performance is subject to risks and uncertainties inherent in clinical trials and regulatory approvals.
- Actual results may differ materially from forward-looking statements.
- The company undertakes no obligation to revise or update information in the release.
- Future success depends on the effectiveness and market adoption of its nsPFA technology.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
-0.0%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+9.3%
Avg return
30 days after
49%
19 / 39 earnings
Positive
+33.9%
Q4 2022
Best reaction
-36.5%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.6% | -4.6% | +34.5% | |
| Q4 2025 | -14.4% | -23.4% | -11.9% | |
| Q3 2025 | -1.2% | -6.1% | -20.0% | |
| Q1 2025 | +1.4% | -3.3% | +1.5% | |
| Q4 2024 | +6.0% | +6.8% | +14.4% | |
| Q3 2024 | +2.3% | -10.9% | +25.6% | |
| Q2 2024 | +8.1% | +21.5% | +9.5% | |
| Q1 2024 | -10.7% | -3.6% | +88.2% | |
| Q4 2023 | -4.9% | -8.5% | -14.4% | |
| Q3 2023 | +12.8% | +18.6% | +95.5% | |
| Q2 2023 | -0.4% | +9.2% | -35.3% | |
| Q1 2023 | -2.5% | -4.6% | -16.0% | |
| Q4 2022 | +33.9% | +57.4% | +156.6% | |
| Q3 2022 | +10.9% | +12.5% | +57.1% | |
| Q2 2022 | +8.7% | +10.6% | +1.2% | |
| Q1 2022 | -36.5% | -7.7% | -3.9% | |
| Q4 2021 | -28.4% | -25.0% | -49.6% | |
| Q3 2021 | -0.2% | -1.5% | -21.4% | |
| Q2 2021 | +7.9% | -2.1% | +2.1% | |
| Q1 2021 | +4.8% | +1.7% | +3.6% | |
| Q4 2020 | -9.2% | -17.5% | -35.1% | |
| Q3 2020 | +15.9% | +22.3% | +40.5% | |
| Q2 2020 | -6.4% | -6.1% | -15.0% | |
| Q1 2020 | +18.8% | -1.7% | -27.2% | |
| Q4 2019 | +21.1% | +5.2% | +14.6% | |
| Q3 2019 | -3.5% | -2.8% | -1.7% | |
| Q2 2019 | -2.5% | +4.6% | +16.1% | |
| Q1 2019 | -32.5% | -22.1% | -26.8% | |
| Q4 2018 | +4.0% | +11.3% | +9.4% | |
| Q3 2018 | +22.7% | +32.7% | +17.3% | |
| Q2 2018 | -0.9% | -6.7% | +4.1% | |
| Q1 2018 | -14.7% | -25.1% | -12.4% | |
| Q4 2017 | +0.1% | +1.8% | +38.5% | |
| Q3 2017 | +9.1% | +18.0% | -11.0% | |
| Q2 2017 | -16.6% | -11.6% | -25.2% | |
| Q1 2017 | -9.5% | -14.7% | +24.9% | |
| Q4 2016 | +6.4% | +18.7% | +12.7% | |
| Q3 2016 | +0.0% | -0.7% | -10.6% | |
| Q2 2016 | +1.5% | +2.2% | +31.3% | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro